ARAY - Accuray Incorporated
| Previous Close | 2.6300 |
| Open | 2.6200 |
| Bid | 2.7000 x 1400 |
| Ask | 2.7100 x 1300 |
| Day's Range | 2.6200 - 2.7150 |
| 52 Week Range | 2.3500 - 5.4000 |
| Volume | 50,628 |
| Avg. Volume | 582,267 |
| Market Cap | 239.71M |
| Beta (3Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1880 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- PR Newswire
Accuray To Report Fiscal 2020 First Quarter Financial Results on October 29, 2019
SUNNYVALE, Calif. , Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. ...
- Zacks
AngioDynamics Boosts VIT Product Portfolio With New Buyout
AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.
- Zacks
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.
- Simply Wall St.
Is It Time To Consider Buying Accuray Incorporated (NASDAQ:ARAY)?
Accuray Incorporated (NASDAQ:ARAY), which is in the medical equipment business, and is based in United States, saw a...
- PR Newswire
Accuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)
SUNNYVALE, Calif., Sept. 19, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes. Titled, "Thriving Under the Radiation Oncology Alternative Payment Model: A Definitive Guide to a New Reality," the guide aims to help radiation oncology professionals understand the changes outlined in the Radiation Oncology – Alternative Payment Model (RO-APM). "We believe that the proposed alternative payment model will reshape economic realities and evolve clinical best practices for radiation oncologists," said Joshua H. Levine, President and Chief Executive Officer of Accuray.
- Zacks
The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks
A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.
- Zacks
Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome
Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.
- PR Newswire
Data Published in The Lancet Oncology Suggest CyberKnife® Prostate Patients Experienced Lower Levels of Acute Genitourinary Toxicity (Grade 2 or Higher) Than Patients Treated on a Conventional Linear Accelerator
SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative Evidence — trial in its most recent issue. While further investigation is planned, data reported in the journal indicate that the level of grade 2 or higher acute genitourinary toxicity in the stereotactic body radiation therapy (SBRT) arm of the trial is lower for patients treated with the Accuray CyberKnife® System than it is for patients treated on a conventional linear accelerator. SBRT involves the delivery of very high doses of externally-administered radiation over a small number of treatment sessions, offering convenience for patients, compared to conventional radiation therapy which requires a substantially longer course of treatment.
- PR Newswire
China Announces Tariff Exclusion for Medical Linear Accelerators
SUNNYVALE, Calif., Sept. 16, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced that, on September 11, 2019, China's Customs Tariff Commission of the State Council issued a tariff exemption for medical linear accelerators. The tariff exemption, which will be effective September 17, 2019 and is scheduled to last for one year, applies to the additional tariffs China imposed on U.S. products effective as of August 23, 2018. Accuray expects to benefit from such tariff exemption. "We applaud the recent decision to exempt medical linear accelerators," said Josh Levine, president and chief executive officer, Accuray.
- Zacks
Why Is Accuray (ARAY) Down 1% Since Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Accuray Appoints Healthcare Veteran James M. Hindman to Board of Directors
SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company's Board to nine members. Mr. Hindman, an experienced healthcare executive with a 30-year tenure at Allergan, Inc., is an accomplished financial executive with expertise in maximizing shareholder value. Mr. Hindman will serve on the Board's Audit Committee.
- PR Newswire
Geisinger Medical Center is First in Pennsylvania to Treat Cancer Patients with Accuray Radixact® System
SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Geisinger Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the innovative Radixact® System. The hospital, located in Danville, is part of Geisinger Health System, one of the United States' most innovative health services organizations. The system's speed, versatility and flexibility will enable the clinical team to provide a treatment option for virtually any case for which radiation therapy is prescribed, including large tumors or multiple tumors throughout the body, hard-to-reach tumors, and tumors that have recurred, including those in patients who may not be candidates for retreatment with traditional delivery systems.
- Zacks
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.
- Simply Wall St.
Have Insiders Been Selling Accuray Incorporated (NASDAQ:ARAY) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- PR Newswire
Accuray to Host ASTRO Investor Meeting on September 16, 2019
Presentations will be Live Webcast and Commence at 3:00pm CT SUNNYVALE, Calif. , Sept. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Investor ...
- Thomson Reuters StreetEvents
Edited Transcript of ARAY earnings conference call or presentation 15-Aug-19 8:30pm GMT
Q4 2019 Accuray Inc Earnings Call
- GuruFocus.com
Accuray Inc (ARAY) Files 10-K for the Fiscal Year Ended on June 30, 2019
Accuray Inc (ARAY) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Continue reading...
- PR Newswire
Froedtert & the Medical College of Wisconsin Cancer Network is First in the World to Treat Cancer Patient Using the Accuray Radixact® System with Synchrony® Motion Tracking and Correction Technology
SUNNYVALE, Calif., Aug. 21, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that physicians at the Froedtert & the Medical College of Wisconsin ("MCW") Clinical Cancer Center at Froedtert Hospital in Milwaukee, Wisconsin have treated the first cancer patient in the world, a 45-year-old man with lung cancer, using the Radixact® System with Synchrony® motion tracking and correction technology1. With the addition of Synchrony, the Radixact System was able to track the lung tumor in real-time as it moved with the patient's breathing and automatically adjust the radiation beam to keep it targeted on the tumor.
- Motley Fool
Here's Why Accuray Stock Is Nosediving Today
Disappointing fourth-quarter results are taking a toll on the medical device stock.
- Zacks
Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates
Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.
- Motley Fool
No Hooray for Accuray in Q4
The CyberKnife maker missed Wall Street bottom-line estimates and announced disappointing guidance for fiscal 2020.
Motley FoolAccuray Inc (ARAY) Q4 2019 Earnings Call Transcript
ARAY earnings call for the period ending June 30, 2019.
- Zacks
Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates
Accuray (ARAY) delivered earnings and revenue surprises of -166.67% and 1.14%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Accuray Reports Fourth Quarter and Fiscal 2019 Financial Results
SUNNYVALE, Calif. , Aug. 15, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2019 . Q4 Fiscal 2019 and Recent ...
- Benzinga
Earnings Outlook For Accuray
Accuray (NASDAQ: ARAY ) unveils its next round of earnings this Thursday, August 15. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Based on Accuray ...
